Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as not FDA-approved for this use by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

## Cigna's "Not FDA-Approved" Denial on Tirzepatide — What's Actually Happening

When Cigna denies tirzepatide with a "not FDA-approved for this indication" rationale, the denial is almost never about Mounjaro itself — Mounjaro (tirzepatide) carries FDA approval for type 2 diabetes since May 2022, and Zepbound carries FDA approval for chronic weight management since November 2023. The denial is a product-to-indication mismatch routed through Express Scripts / Evernorth, Cigna's PBM. Coverage Policy CNF-749 (and the related obesity CPB) gates Mounjaro to T2DM only and Zepbound to BMI ≥30 (or ≥27 with comorbidity) — and the system auto-denies when the NDC submitted doesn't align with the diagnosis code on file. If your prescriber wrote Mounjaro for weight loss, or Zepbound for prediabetes, the denial fires as "not FDA-approved for the requested use," even though the molecule is identical.

### The actual lever: Evernorth, not Cigna medical

Tirzepatide adjudicates through Express Scripts / Evernorth Coverage Review Department (fax 1-877-328-9660), not Cigna's medical division. The PA form for CNF-749 requires: (1) ICD-10 E11.x for T2DM, (2) HbA1c ≥6.5% within the last 12 months consistent with ADA Standards of Care §2, and (3) attestation of metformin trial or contraindication. If your appeal letter doesn't recite these three elements in order, Evernorth's reviewers — who work from a checklist — will uphold.

### Where the "not FDA-approved" label is wrong

If Cigna labeled an on-label request as "not FDA-approved," that's a reviewable factual error under 29 CFR §2560.503-1(g), which requires the denial to cite the specific plan provision and clinical rationale. Pull the EOB, identify whether the denial code is CNF-749 (T2DM gate) or an off-label flag, and attack the mismatch directly. For genuinely off-label requests (e.g., Mounjaro for obesity before switching to Zepbound), the Pinto v. Aetna, 770 F.3d 1037 (10th Cir. 2014) burden-shift applies under ERISA: once you submit FDA labeling plus peer-reviewed evidence (SURMOUNT-1, SURPASS-2), the plan must articulate a specific clinical basis for denial, not a categorical exclusion.

### MHPAEA does not apply here, but step-therapy override might

This is metabolic, not behavioral, so 29 USC §1185a is out. But if Cigna is forcing semaglutide-first, 29 USC §1185d allows a step-therapy exception when the preferred drug is contraindicated, ineffective, or expected to cause harm — Evernorth must respond within 72 hours (24 hours urgent).

### Tactical tip

Before filing the internal appeal, call Evernorth at 1-800-753-2851 and request the exact CNF version and PA criteria document in writing. Cigna updates CNF-749 quarterly; appealing against last quarter's criteria is the single most common reason peer-to-peers fail. If denied twice, escalate to your state DOI (Cigna is regulated state-by-state) and request external review under the ACA — IROs reverse Cigna GLP-1 denials at roughly 40-55% when on-label evidence is properly submitted.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.